ClinicalTrials.gg

Program

HRS-9821

A development code. Also written as “HRS-9821 Powder for Inhalation/HRS-9821 inhalation suspension”, “HRS-9821 Inhalation Suspension” and “HRS-9821 Powder for Inhalation”.

In Jiangsu HengRui Medicine's pipeline, PDE3/4. Its studies are mostly in Pulmonary Disease, Chronic Obstructive, led by Jiangsu HengRui Medicine.

Furthest: phase 2, since Jun 1, 20264 company-led studies, 2 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Jiangsu HengRui Medicine42 open or runningphase 2since Jun 1, 2026Nov 14, 2022none ahead
  • Named in Jiangsu HengRui Medicine’s own pipeline as HRS-9821, phase 2, as of Jul 31, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 14, 2022First study: phase 1 study in Pulmonary Disease, Chronic ObstructiveFirst studyNCT05622864 · 106 enrolled · China
  2. Jul 22, 2025Phase 1 study in Pulmonary Disease, Chronic ObstructiveNCT07116915 · 85 enrolled · China
  3. Apr 28, 2026Phase 1 study in Pulmonary Disease, Chronic ObstructiveNCT07567872 · 48 planned · China
  4. Jun 1, 2026Phase 2 study in Pulmonary Disease, Chronic ObstructivePhase 2 reachedNCT07640451 · 90 planned · China

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07640451Pulmonary Disease, Chronic Obstructive · China2RecruitingOct 202690
NCT07567872Pulmonary Disease, Chronic Obstructive · China1RecruitingSep 202648
NCT07116915Pulmonary Disease, Chronic Obstructive · China1CompletedAug 14, 202685
NCT05622864Pulmonary Disease, Chronic Obstructive · China1CompletedMay 7, 2025106

How it is read

Names in the registry

  • “HRS-9821 Powder for Inhalation/HRS-9821 inhalation suspension”, 2 entries
  • “HRS-9821”, 2 entries
  • “HRS-9821 Inhalation Suspension”, 1 entry
  • “HRS-9821 Powder for Inhalation”, 1 entry

Codes read as this program: HRS9821.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.